ReportsnReports – Biochips Market (DNA Microarrays, Lab-on-Chip, Protein Microarrays, Tissue & Cell Arrays) Trends & Global Forecast (2010-2015)

Document Sample
ReportsnReports – Biochips Market (DNA Microarrays, Lab-on-Chip, Protein Microarrays, Tissue & Cell Arrays) Trends & Global Forecast (2010-2015) Powered By Docstoc
					Biochips Market (DNA Microarrays, Lab-on-Chip, Protein Microarrays, Tissue & Cell
Arrays) Trends & Global Forecast (2010-2015)



ReportsnReports.com adds MarketsandMarkets Market Research Report “ Biochips Market
(DNA Microarrays, Lab-on-Chip, Protein Microarrays, Tissue & Cell Arrays) Trends & Global
Forecast (2010-2015)’’ to its store.

A biochip is defined as a collection of miniaturized test sites (microarrays) arranged on a
solid platform that allows multiple tests to be performed at the same time with increased
efficiency and higher speed. The global biochip market is studied by the types and key
applications. It was valued at $2.6 billion in 2010 and is expected to reach $5.6 billion by
2015; growing at a CAGR of 16.7%. This growth is attributed to increasing applications in
cancer diagnostics and expression profiling, the boom in personalized medicine, and
government funding.

DNA microarrays represent the largest segment of this market and will continue to be the
largest contributor during the study period (2010-2015). However, this segment will be
closely followed by lab-on-chip (LOC) in the coming years due to its wide applications and
increased adoption by various biotechnology, pharmaceutical companies, and research
laboratories. The third largest segment – protein microarrays will be the fastest growing
segment; forecasted to grow at a CAGR of 19.9% during the study period due to advances
in the fields of genomics and proteomics and improvements in the field of recombinant
proteins.
Reverse phase protein microarrays designed for targeted therapies in cancer holds promise
in the global biochip market in the next 5-10 years. These microarrays provide increased
accuracy and enhanced efficacy for the detection of rare molecules as compared to existing
microarray surfaces for cancer research & diagnosis to help understand the proteins in
tumor cells. Thus, they have helped open the avenues for personalized methods for cancer
therapy.
The market of Asia will account for a bulk of the future biochip market growth due to its
high growth potential and huge demand from emerging economies such as India and China
– the large pool of heterogeneous patient population, and increasing R&D investment in
these countries. The top players in the biochip market such as Affymetrix, Inc., Illumina,
Inc., and Fluidigm Corporation have relocated their manufacturing base to Singapore to take
advantage of the benefits the country offers; coupled with rising demand from neighboring
countries of Asia. The players also benefit from a well-established semiconductor
manufacturing base including chip technologies. Singapore has made focused efforts to
attract life sciences corporates with dedicated investments accounting for 3% of the
country’s GDP. It came up with its R&D center – Singapore’s Biopolis R&D center in 2003-
2004 and is home to the Genome Institute of Singapore.

Scope of the report

This research report categorizes the global biochips market on the basis of applications,
types, and geography; forecasting revenues and analyzing trends in each of the following
submarkets:
On the basis of applications:

DNA applications: Gene expression, SNP genotyping, cancer diagnosis & treatment,
genomics, agricultural biotechnology, drug discovery, and others.
Lab on chip applications: Drug discovery, genomics, diagnostics, proteomics, IVD & POC,
high throughput screening, and others.
Protein microarray applications: Expression profiling, proteomics, high throughput
screening, diagnostics, drug discovery, and others.
Other array applications: Expression profiling, cancer diagnostics, toxicogenomics,
genomics, drug discovery, and others.

On the basis of types:
DNA microarrays, lab on chip, protein microarrays, other arrays (cell arrays and
tissue arrays)

On the basis of geography:

North America, Europe, Asia, and Rest of the World.

Each section will provide market data, market drivers, trends and opportunities, top-selling
products, key players, and competitive outlook. It will also provide market tables for
covering the sub-segments. In addition, the report will throw light on more than 20
company profiles covering all the sub-segments.

TABLE OF CONTENTS

1 INTRODUCTION

1.1 KEY TAKE-AWAYS
1.2 REPORT DESCRIPTION
1.3 MARKETS COVERED
1.4 STAKEHOLDERS
1.5 RESEARCH METHODOLOGY
1.5.1 MARKET SIZE
1.5.2 KEY DATA POINTS FROM SECONDARY SOURCES
1.5.3 KEY DATA POINTS FROM PRIMARY SOURCES
1.5.4 MARKET SHARE
1.5.5 ASSUMPTIONS MADE FOR THE REPORT

2 EXECUTIVE SUMMARY

2.1 OVERVIEW OF THE MARKET
2.2 KEY FINDINGS
2.3 RECOMMENDATIONS
2.3.1 APPLICATION OF REVERSE PHASE PROTEIN MICROARRAYS IN CANCER DIAGNOSIS IS
A LUCRATIVE INVESTMENT OPTION

3 MARKET OVERVIEW
3.1 INTRODUCTION
3.2 BURNING ISSUE
3.2.1 EMERGENCE OF NEW DISEASES & DISEASE COMPLEXITY CATALYZE ADOPTION OF
BIOCHIPS IN DIAGNOSTICS
3.3 WINNING IMPERATIVES
3.3.1 STANDARDIZATION IS A NECESSITY
3.3.2 COST
3.3.3 NEED OF CROSS COMPATIBILITY
3.3.4 END-TO-END SOLUTIONS
3.4 MARKET DYNAMICS
3.4.1 DRIVERS
3.4.1.1 Growth in personalized medicine
3.4.1.2 Increase Government funding
3.4.1.3 Cancer diagnosis & treatment is on a rise
3.4.1.4 Technical advances
3.4.2 RESTRAINTS
3.4.2.1 Knowledge constraints with respect to technical know-how
3.4.2.2 Lack of healthcare coverage restricts the adoption
3.4.3 OPPORTUNITIES
3.4.3.1 Growth of market in the sub-continent of Asia
3.4.3.2 Widening applications market
3.4.4 TRENDS
3.4.4.1 Robust deals & alliances
3.4.4.2 Relocating manufacturing facilities to gain competitive edge
3.4.4.2.1 Advantage Singapore
3.4.4.3 Next generation technology for LOC
3.4.4.3.1 Lab on CD-ROM
3.4.4.3.2 EFAD chip technology
3.4.4.4 Outsourcing of the biochip technology
3.4.4.4.1 Reduction in the labor cost
3.4.4.4.2 Increased focus on core business
3.4.4.4.3 Risk reduction
3.4.4.4.4 Utilization of business expertise
3.4.4.4.5 Reduction in capital expenditure
3.5 MARKET BREAKDOWN
3.6 END-USER ANALYSIS
3.7 MARKET SHARE ANALYSIS
3.7.1 DNA MICROARRAY MARKET SHARE ANALYSIS
3.7.2 LOC/MICROFLUIDICS MARKET SHARE ANALYSIS
3.7.3 PROTEIN MICROARRAY MARKET SHARE ANALYSIS

4 GLOBAL DNA MICROARRAY MARKET

4.1 INTRODUCTION
4.2 DNA MICROARRAY MARKET, BY APPLICATIONS
4.2.1 GENE EXPRESSION
4.2.2 SNP GENOTYPING
4.2.3 CANCER DIAGNOSIS & TREATMENT
4.2.4   GENOMICS
4.2.5   AGRICULTURAL BIOTECHNOLOGY
4.2.6   DRUG DISCOVERY
4.2.7   OTHERS

5 GLOBAL LAB-ON-CHIP/MICROFLUIDICS MARKET

5.1 INTRODUCTION
5.2 LOC/MICROFLUIDICS MARKET, BY APPLICATIONS
5.2.1 HIGH THROUGHPUT SCREENING
5.2.2 GENOMICS
5.2.3 PROTEOMICS
5.2.4 DRUG DISCOVERY
5.2.5 IVD & POC
5.2.6 DIAGNOSTICS
5.2.7 OTHERS

6 GLOBAL PROTEIN MICROARRAY MARKET

6.1 INTRODUCTION
6.2 PROTEIN MICROARRAY MARKET, BY TYPES
6.2.1 EXPRESSIONAL PROTEIN MICROARRAY
6.2.2 FUNCTIONAL PROTEIN MICROARRAY
6.2.3 REVERSE PHASE PROTEIN MICROARRAY
6.3 PROTEIN MICROARRAY MARKET, BY APPLICATIONS
6.3.1 EXPRESSION PROFILING
6.3.2 PROTEOMICS
6.3.3 HIGH THROUGHPUT SCREENING
6.3.4 DIAGNOSTICS
6.3.5 DRUG DISCOVERY
6.3.6 OTHERS

7 GLOBAL OTHER ARRAYS MARKET

7.1 OTHER ARRAYS MARKET, BY TYPES
7.1.1 CELL ARRAY
7.1.2 TISSUE ARRAY
7.1.2.1 FFPE Arrays
7.1.2.2 Frozen Arrays
7.2 OTHER ARRAYS MARKET, BY APPLICATIONS
7.2.1 EXPRESSION PROFILING
7.2.2 CANCER DIAGNOSTICS
7.2.3 TOXICOGENOMICS
7.2.4 GENOMICS
7.2.5 DRUG DISCOVERY
7.2.6 OTHERS

8 GLOBAL BIOCHIP MARKET, BY GEOGRAPHY
8.1 INTRODUCTION
8.2 NORTH AMERICA
8.3 EUROPE
8.4 ASIA
8.5 ROW
9 COMPETITIVE LANDSCAPE

9.1 KEY STRATEGIES

10 COMPANY PROFILES

10.1 AFFYMETRIX INC
10.1.1 OVERVIEW
10.1.2 FINANCIALS
10.1.3 PRODUCTS & SERVICES
10.1.4 STRATEGY
10.1.5 DEVELOPMENTS
10.2 AGILENT TECHNOLOGIES INC
10.2.1 OVERVIEW
10.2.2 FINANCIALS
10.2.3 PRODUCTS & SERVICES
10.2.4 STRATEGY
10.2.5 DEVELOPMENTS
10.3 BIOCHAIN INSTITUTE INC
10.3.1 OVERVIEW
10.3.2 FINANCIALS
10.3.3 PRODUCTS & SERVICES
10.3.4 STRATEGY
10.3.5 DEVELOPMENTS
10.4 BIOMÉRIEUX SA
10.4.1 OVERVIEW
10.4.2 FINANCIALS
10.4.3 PRODUCTS & SERVICES
10.4.4 STRATEGY
10.4.5 DEVELOPMENTS
10.5 BIO-RAD LABORATORIES INC
10.5.1 OVERVIEW
10.5.2 FINANCIALS
10.5.3 PRODUCTS & SERVICES
10.5.4 STRATEGY
10.5.5 DEVELOPMENTS
10.6 CALIPER LIFE SCIENCES INC
10.6.1 OVERVIEW
10.6.2 FINANCIALS
10.6.3 PRODUCTS & SERVICES
10.6.4 STRATEGY
10.6.5 DEVELOPMENTS
10.7 CEPHEID INC
10.7.1 OVERVIEW
10.7.2 FINANCIALS
10.7.3 PRODUCTS & SERVICES
10.7.4 STRATEGY
10.7.5 DEVELOPMENTS
10.8 CYBRDI INC
10.8.1 OVERVIEW
10.8.2 FINANCIALS
10.8.3 PRODUCTS & SERVICES
10.8.4 STRATEGY
10.8.5 DEVELOPMENTS
10.9 EMD MILLIPORE
10.9.1 OVERVIEW
10.9.2 FINANCIALS
10.9.3 PRODUCTS & SERVICES
10.9.4 STRATEGY
10.9.5 DEVELOPMENTS
10.10 FLUIDIGM CORP
10.10.1 OVERVIEW
10.10.2 FINANCIALS
10.10.3 PRODUCTS & SERVICES
10.10.4 STRATEGY
10.10.5 DEVELOPMENTS
10.11 GAMIDA FOR LIFE GROUP
10.11.1 OVERVIEW
10.11.2 FINANCIALS
10.11.3 PRODUCTS & SERVICES
10.11.4 STRATEGY
10.11.5 DEVELOPMENTS
10.12 ILLUMINA INC
10.12.1 OVERVIEW
10.12.2 FINANCIALS
10.12.3 PRODUCTS & SERVICES
10.12.4 STRATEGY
10.12.5 DEVELOPMENTS
10.13 LIFE TECHNOLOGIES CORP
10.13.1 OVERVIEW
10.13.2 FINANCIALS
10.13.3 PRODUCTS & SERVICES
10.13.4 STRATEGY
10.13.5 DEVELOPMENTS
10.14 ORIGENE TECHNOLOGIES INC
10.14.1 OVERVIEW
10.14.2 FINANCIALS
10.14.3 PRODUCTS & SERVICES
10.14.4 STRATEGY
10.14.5 DEVELOPMENTS
10.15 PERKINELMER INC
10.15.1 OVERVIEW
10.15.2 FINANCIALS
10.15.3 PRODUCTS & SERVICES
10.15.4 STRATEGY
10.15.5 DEVELOPMENTS
10.16 ROCHE NIMBLEGEN INC
10.16.1 OVERVIEW
10.16.2 FINANCIALS
10.16.3 PRODUCTS & SERVICES
10.16.4 STRATEGY
10.16.5 DEVELOPMENTS
10.17 SEQUENOM
10.17.1 OVERVIEW
10.17.2 FINANCIALS
10.17.3 PRODUCTS & SERVICES
10.17.4 STRATEGY
10.17.5 DEVELOPMENTS
10.18 SIGMA ALDRICH CORP
10.18.1 OVERVIEW
10.18.2 FINANCIALS
10.18.3 PRODUCTS & SERVICES
10.18.4 STRATEGY
10.18.5 DEVELOPMENTS
10.19 OTHERS
10.19.1 IMGENEX
10.19.1.1 Overview
10.19.1.2 Financials
10.19.1.3 Products & services
10.19.2 ISU ABXIS CO. LTD
10.19.2.1 Overview
10.19.2.2 Financials
10.19.2.3 Products & services
10.19.3 US BIOMAX INC
10.19.3.1 Overview
10.19.3.2 Financials
10.19.3.3 Products & services

LIST OF TABLES

TABLE 1 GLOBAL BIOCHIP MARKET REVENUE, BY PRODUCTS, 2008 – 2015 ($MILLION)
TABLE 2 LIFE EXPECTANCY AT BIRTH
TABLE 3 TAX ENVIRONMENT
TABLE 4 TAX ENVIRONMENT: FOR NEW START UP COMPANIES IN SINGAPORE
TABLE 5 DNA MICROARRAY MARKET REVENUE, BY GEOGRAPHY, 2008 – 2015 ($MILLION)
TABLE 6 TOP FIVE DNA MICROARRAY TECHNOLOGIES
TABLE 7 COMPARISON BETWEEN PHOTOLITHOGRAPHY & INKJET TECHNOLOGY
TABLE 8 GLOBAL DNA MICROARRAY MARKET REVENUE, BY APPLICATIONS, 2008 – 2015
($MILLION)
TABLE 9 DNA MICROARRAY: GENE EXPRESSION MARKET REVENUE, BY GEOGRAPHY, 2008
– 2015 ($MILLION)
TABLE 10 DNA MICROARRAY: SNP GENOTYPING MARKET REVENUE, BY GEOGRAPHY, 2008
– 2015 ($MILLION)
TABLE 11 DNA MICROARRAY: CANCER DIAGNOSIS & TREATMENT MARKET REVENUE, BY
GEOGRAPHY, 2008 – 2015 ($MILLION)
TABLE 12 DNA MICROARRAY: GENOMICS MARKET REVENUE, BY GEOGRAPHY, 2008 – 2015
($MILLION)
TABLE 13 DNA MICROARRAY: AGRICULTURAL BIOTECHNOLOGY MARKET REVENUE, BY
GEOGRAPHY, 2008 – 2015 ($MILLION)
TABLE 14 DNA MICROARRAY: DRUG DISCOVERY MARKET REVENUE, BY GEOGRAPHY, 2008
– 2015 ($MILLION)
TABLE 15 DNA MICROARRAY: OTHERS MARKET REVENUE, BY GEOGRAPHY, 2008 – 2015
($MILLION)
TABLE 16 LOC MARKET REVENUE, BY GEOGRAPHY, 2008 – 2015 ($MILLION)
TABLE 17 GLOBAL LOC MARKET REVENUE, BY APPLICATIONS, 2008 – 2015 ($MILLION)
TABLE 18 COMPARATIVE ANALYSIS OF MICROFLUIDIC ASSAY TECHNIQUES
TABLE 19 LOC: HTS MARKET REVENUE, BY GEOGRAPHY, 2008 – 2015 ($MILLION)
TABLE 20 LOC: GENOMICS MARKET REVENUE, BY GEOGRAPHY, 2008 – 2015 ($MILLION)
TABLE 21 LOC: PROTEOMICS MARKET REVENUE, BY GEOGRAPHY, 2008 – 2015 ($MILLION)
TABLE 22 LOC: DRUG DISCOVERY MARKET REVENUE, BY GEOGRAPHY, 2008 – 2015
($MILLION)
TABLE 23 LOC: IVD & POC MARKET REVENUE, BY GEOGRAPHY, 2008 – 2015 ($MILLION)
TABLE 24 LOC: DIAGNOSTICS MARKET REVENUE, BY GEOGRAPHY, 2008 – 2015
($MILLION)
TABLE 25 LOC: OTHERS MARKET REVENUE, BY GEOGRAPHY, 2008 – 2015 ($MILLION)
TABLE 26 PROTEIN MICROARRAY MARKET REVENUE, BY GEOGRAPHY, 2008 – 2015
($MILLION)
TABLE 27 PROTEIN MICROARRAY MANUFACTURING TECHNOLOGIES
TABLE 28 GLOBAL PROTEIN MICROARRAY MARKET REVENUE, BY TYPES, 2008 – 2015
($MILLION)
TABLE 29 EXPRESSIONAL PROTEIN MICROARRAY MARKET REVENUE, BY GEOGRAPHY, 2008
– 2015 ($MILLION)
TABLE 30 FUNCTIONAL PROTEIN MICROARRAY MARKET REVENUE, BY GEOGRAPHY, 2008 –
2015 ($MILLION)
TABLE 31 REVERSE PHASE PROTEIN MICROARRAY MARKET REVENUE, BY GEOGRAPHY,
2008 – 2015 ($MILLION)
TABLE 32 GLOBAL PROTEIN MICROARRAY MARKET REVENUE, BY APPLICATIONS, 2008 –
2015 ($MILLION)
TABLE 33 PROTEIN MICROARRAY APPLICATIONS IN EXPRESSION PROFILING
TABLE 34 PROTEIN MICROARRAY: EXPRESSION PROFILING MARKET REVENUE, BY
GEOGRAPHY, 2008 – 2015 ($MILLION)
TABLE 35 PROTEIN MICROARRAY APPLICATIONS IN PROTEOMICS
TABLE 36 PROTEIN MICROARRAY: PROTEOMICS MARKET REVENUE, BY GEOGRAPHY, 2008
– 2015 ($MILLION)
TABLE 37 PROTEIN MICROARRAY: HTS MARKET REVENUE, BY GEOGRAPHY, 2008 – 2015
($MILLION)
TABLE 38 PROTEIN MICROARRAY: DIAGNOSTICS MARKET REVENUE, BY GEOGRAPHY, 2008
– 2015 ($MILLION)
TABLE 39 PROTEIN MICROARRAY: DRUG DISCOVERY MARKET REVENUE, BY GEOGRAPHY,
2008 – 2015 ($MILLION)
TABLE 40 PROTEIN MICROARRAY: OTHERS MARKET REVENUE, BY GEOGRAPHY, 2008 –
2015 ($MILLION)
TABLE 41 GLOBAL OTHER ARRAYS MARKET REVENUE, BY TYPES, 2008 – 2015 ($MILLION)
TABLE 42 OTHER ARRAYS MARKET REVENUE, BY GEOGRAPHY, 2008 – 2015 ($MILLION)
TABLE 43 CELL ARRAYS MARKET REVENUE, BY GEOGRAPHY, 2008 – 2015 ($MILLION)
TABLE 44 GLOBAL TISSUE ARRAYS MARKET REVENUE, BY PRODUCTS, 2008 – 2015
($MILLION)
TABLE 45 TISSUE ARRAYS MARKET REVENUE, BY GEOGRAPHY, 2008 – 2015 ($MILLION)
TABLE 46 FFPE ARRAYS MARKET REVENUE, BY GEOGRAPHY, 2008 – 2015 ($MILLION)
TABLE 47 FROZEN ARRAYS MARKET REVENUE, BY GEOGRAPHY, 2008 – 2015 ($MILLION)
TABLE 48 GLOBAL OTHER ARRAYS MARKET REVENUE, BY APPLICATIONS, 2008 – 2015
($MILLION)
TABLE 49 OTHER ARRAYS: EXPRESSION PROFILING MARKET REVENUE, BY GEOGRAPHY,
2008 – 2015 ($MILLION)
TABLE 50 OTHER ARRAYS: CANCER DIAGNOSTICS MARKET REVENUE, BY GEOGRAPHY,
2008 – 2015 ($MILLION)
TABLE 51 OTHER ARRAYS: TOXICOGENOMICS MARKET REVENUE, BY GEOGRAPHY, 2008 –
2015 ($MILLION)
TABLE 52 OTHER ARRAYS: GENOMICS MARKET REVENUE, BY GEOGRAPHY, 2008 – 2015
($MILLION)
TABLE 53 OTHER ARRAYS: DRUG DISCOVERY MARKET REVENUE, BY GEOGRAPHY, 2008 –
2015 ($MILLION)
TABLE 54 OTHER ARRAYS: OTHERS MARKET REVENUE, BY GEOGRAPHY, 2008 – 2015
($MILLION)
TABLE 55 BIOCHIP MARKET REVENUE, BY GEOGRAPHY, 2008 – 2015 ($MILLION)
TABLE 56 NORTH AMERICA: BIOCHIP MARKET REVENUE, BY PRODUCTS, 2008 – 2015
($MILLION)
TABLE 57 NORTH AMERICA: DNA MICROARRAY MARKET REVENUE, BY APPLICATIONS, 2008
– 2015 ($MILLION)
TABLE 58 NORTH AMERICA: PROTEIN MICROARRAY MARKET REVENUE,BY PRODUCTS, 2008
– 2015 ($MILLION)
TABLE 59 NORTH AMERICA: PROTEIN MICROARRAY MARKET REVENUE, BY APPLICATIONS,
2008 – 2015 ($MILLION)
TABLE 60 NORTH AMERICA: LOC MARKET REVENUE, BY APPLICATIONS, 2008 – 2015
($MILLION)
TABLE 61 NORTH AMERICA: OTHER ARRAYS MARKET REVENUE, BY PRODUCTS, 2008 –
2015 ($MILLION)
TABLE 62 NORTH AMERICA: OTHER ARRAYS MARKET REVENUE, BY APPLICATIONS, 2008 –
2015 ($MILLION)
TABLE 63 EUROPE: BIOCHIP MICROARRAY MARKET REVENUE, BY PRODUCTS, 2008 – 2015
($MILLION)
TABLE 64 EUROPE: DNA MICROARRAY MARKET REVENUE, BY APPLICATIONS, 2008 – 2015
($MILLION)
TABLE 65 EUROPE: PROTEIN MICROARRAY MARKET REVENUE, BY PRODUCTS, 2008 – 2015
($MILLION)
TABLE 66 EUROPE: PROTEIN MICROARRAY MARKET REVENUE, BY APPLICATIONS, 2008 –
2015 ($MILLION)
TABLE 67 EUROPE: LOC MARKET REVENUE, BY APPLICATIONS, 2008 – 2015 ($MILLION)
TABLE 68 EUROPE: OTHER ARRAYS MARKET REVENUE, BY PRODUCTS, 2008 – 2015
($MILLION)
TABLE 69 EUROPE: OTHER ARRAYS MARKET REVENUE, BY APPLICATIONS, 2008 – 2015
($MILLION)
TABLE 70 ASIA: BIOCHIP MARKET REVENUE, BY PRODUCTS, 2008 – 2015 ($MILLION)
TABLE 71 ASIA: DNA MICROARRAY MARKET REVENUE, BY APPLICATIONS, 2008 – 2015
($MILLION)
TABLE 72 ASIA: PROTEIN MICROARRAY MARKET REVENUE, BY PRODUCTS, 2008 – 2015
($MILLION)
TABLE 73 ASIA: PROTEIN MICROARRAY MARKET REVENUE, BY APPLICATIONS, 2008 – 2015
($MILLION)
TABLE 74 ASIA: LOC MARKET REVENUE, BY APPLICATIONS, 2008 – 2015 ($MILLION)
TABLE 75 ASIA: OTHER ARRAYS MARKET REVENUE, BY PRODUCTS, 2008 – 2015
($MILLION)
TABLE 76 ASIA: OTHER ARRAYS MARKET REVENUE, BY APPLICATIONS, 2008 – 2015
($MILLION)
TABLE 77 ROW: BIOCHIP MARKET REVENUE, BY PRODUCTS, 2008 – 2015 ($MILLION)
TABLE 78 ROW: DNA MICROARRAY MARKET REVENUE, BY APPLICATIONS, 2008 – 2015
($MILLION)
TABLE 79 ROW: PROTEIN MICROARRAY MARKET REVENUE, BY PRODUCTS, 2008 – 2015
($MILLION)
TABLE 80 ROW: PROTEIN MICROARRAY MARKET REVENUE, BY APPLICATIONS, 2008 – 2015
($MILLION)
TABLE 81 ROW: LOC MARKET REVENUE, BY APPLICATIONS, 2008 – 2015 ($MILLION)
TABLE 82 ROW: OTHER ARRAYS MARKET REVENUE, BY PRODUCTS, 2008 – 2015
($MILLION)
TABLE 83 ROW: OTHER ARRAYS MARKET REVENUE, BY APPLICATIONS, 2008 – 2015
($MILLION)
TABLE 84 NEW PRODUCT LAUNCHES
TABLE 85 AGREEMENTS & COLLABORATIONS
TABLE 86 MERGERS & ACQUISITIONS
TABLE 87 AFFYMETRIX INC: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010
($MILLION)
TABLE 88 AFFYMETRIX INC: TOTAL REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION)
TABLE 89 AFFYMETRIX INC: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION)
TABLE 90 AGILENT TECHNOLOGIES: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010
($MILLION)
TABLE 91 AGILENT TECHNOLOGIES: TOTAL REVENUE, BY GEOGRAPHY, 2008 – 2010
($MILLION)
TABLE 92 AGILENT TECHNOLOGIES: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010
($MILLION)
TABLE 93 BIOMÉRIEUX SA: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)
TABLE 94 BIO-RAD LABORATORIES: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010
($MILLION)
TABLE 95 BIO-RAD LABORATORIES: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010
($MILLION)
TABLE 96 BIO-RAD LABORATORIES: MARKET REVENUE, BY GEOGRAPHY, 2008 – 2010
($MILLION)
TABLE 97 CALIPER LIFE SCIENCES INC: TOTAL REVENUE AND R&D EXPENSES, 2008 –
2010 ($THOUSAND)
TABLE 98 CALIPER LIFE SCIENCES INC:TOTAL REVENUE, BY GEOGRAPHY, 2008 – 2010
($THOUSAND)
TABLE 99 CALIPER LIFE SCIENCES INC: TOTAL REVENUE, BY SEGMENTS, 2009 – 2010
($THOUSAND)
TABLE 100 CEPHEID INC.: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010
($THOUSAND)
TABLE 101 CEPHEID: TOTAL PRODUCT REVENUE, BY GEOGRAPHY, 2008 – 2010
($THOUSAND)
TABLE 102 CEPHEID: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($THOUSAND)
TABLE 103 CEPHEID: TOTAL REVENUE, BY SUB-SEGMENTS, 2008 – 2010 ($THOUSAND)
TABLE 104 CYBRDI INC: TOTAL REVENUE AND R&D EXPENSES, 2009 – 2010 ($THOUSAND)
TABLE 105 CYBRDI INC: TOTAL REVENUE, BY COUNTRY, 2009 – 2010 ($THOUSAND)
TABLE 106 CYBRDI INC: TOTAL REVENUE, BY SEGMENTS ($THOUSAND)
TABLE 107 FLUIDIGM CORP: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010
($THOUSAND)
TABLE 108 FLUIDIGM CORP: TOTAL PRODUCTS REVENUE, BY GEOGRAPHY, 2008 – 2010
($THOUSAND)
TABLE 109 FLUIDIGM CORP: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($THOUSAND)
TABLE 110 ILLUMINA INC: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010
($THOUSAND)
TABLE 111 ILLUMINA INC: TOTAL REVENUE, BY GEOGRAPHY, 2008 – 2010 ($THOUSAND)
TABLE 112 ILLUMINA INC: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($THOUSAND)
TABLE 113 LIFE TECHNOLOGIES CORP: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010
($MILLION)
TABLE 114 LIFE TECHNOLOGIES CORP: TOTAL REVENUE, BY GEOGRAPHY, 2008 – 2010
($THOUSAND)
TABLE 115 LIFE TECHNOLOGIES CORP: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010
($MILLION)
TABLE 116 PERKINELMER INC: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010
($MILLION)
TABLE 117 PERKINELMER INC: TOTAL REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION)
TABLE 118 PERKINELMER INC: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION)
TABLE 119 SEQUENOM INC: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010
($THOUSAND)
TABLE 120 SEQUENOM INC: TOTAL REVENUE, BY GEOGRAPHY, 2008 – 2010 ($THOUSAND)
TABLE 121 SEQUENOM INC: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($THOUSAND)
TABLE 122 SIGMA-ALDRICH: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010
($MILLION)
TABLE 123 SIGMA-ALDRICH: TOTAL REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION)
TABLE 124 SIGMA-ALDRICH: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION)
TABLE 125 ISU ABXIS CO. LTD: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010
($THOUSAND)

LIST OF FIGURES

FIGURE   1   BIOCHIP MARKET SEGMENTATION
FIGURE   2   GLOBAL BIOCHIP MARKET, 2010 VS 2015
FIGURE   3   MARKET COMPOSITION, 2010
FIGURE   4   COMPOSITION OF END-USERS, 2010
FIGURE   5 DNA MICROARRAY MARKET SHARE ANALYSIS, BY COMPANIES, 2010
FIGURE   6 GLOBAL LAB-ON-CHIP MARKET SHARE ANALYSIS, BY COMPANIES, 2010
FIGURE   7 GLOBAL PROTEIN MICROARRAY MARKET SHARE ANALYSIS, BY COMPANIES, 2010
FIGURE   8 DNA MICROARRAY MARKET – APPLICATIONS MARKET SEGMENTATION
FIGURE   9 LAB-ON-CHIP APPLICATIONS MARKET SEGMENTATION
FIGURE   10 APPLICATION OF LAB-ON-CHIP TECHNOLOGY IN DRUG DISCOVERY
FIGURE   11 PROTEIN MICROARRAY APPLICATIONS MARKET SEGMENTATION
FIGURE   12 KEY GROWTH STRATEGIES, JANUARY 2008 – JUNE 2011

Latest Market Research Reports

Global Nuclear Medicine (Medical Isotopes/ Radioisotopes/ Radiopharmaceuticals) Market in
PET/SPECT Imaging and Therapy – Competitive Landscape, Current trends and Forecasts
(2010 – 2015)
Medical Imaging Markets: Image-Guided Surgery
July Monthly Deal Roundup – Foodservice
The Future of Interior Products in Spain to 2015: Demand to Gather Pace from 2012
Global and China Rubber Auxiliary Industry Report, 2010-2011
China Ceramic Industry Report, 2010-2011
China Online Video Industry Report, 2011

About Us:
ReportsnReports is an online library of over 75,000 market research reports and in-depth
market research studies & analysis of over 5000 micro markets. We provide 24/7 online and
offline support to our customers. Get in touch with us for your needs of market research
reports.
Follow us on Twitter: http://twitter.com/marketsreports
Our Facebook Page: http://www.facebook.com/pages/ReportsnReports/191441427571689

Contact:
Mr. Priyank
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004 EXT 106
E-mail: sales@reportsandreports.com
http://www.reportsnreports.com
Visit Our Market Research Blog

				
DOCUMENT INFO
Description: A biochip is defined as a collection of miniaturized test sites (microarrays) arranged on a solid platform that allows multiple tests to be performed at the same time with increased efficiency and higher speed. The global biochip market is studied by the types and key applications. It was valued at $2.6 billion in 2010 and is expected to reach $5.6 billion by 2015; growing at a CAGR of 16.7%. This growth is attributed to increasing applications in cancer diagnostics and expression profiling, the boom in personalized medicine, and government funding.